Novavax Inc (NVAX)
$15.75
0.81 (5.42%)
NVAX Stock Quote Delayed 30 Minutes
Merck’s Good News Doesn’t End the Bullish Story for Novavax
Investors are pointing fingers at Merck, but a tricky start to October could yet turn into a treat for buyers of NVAX stock
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
1.17B
PE Ratio
-4.92
EPS
-3.2
Volume (Avg. Vol.)
3.05M
Day's Range
$14.65 - $15.79
52-Week Range
$3.53 - $23.86
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and Novavax Inc News
Novavax News: Why NVAX Stock Investors Have a Tough Pill to Swallow Today
Novavax (NVAX) stock is taking a beating on Friday as investors react to news about Merck (MRK) developing a COVID-19 treatment.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, investor! The final day of the workweek is here and with it comes a look at the pre-market stock movers for Friday!
Novavax Stock is Set to Soar in the Year Ahead
The potential rewards in NVAX stock far outweigh the risks as the vaccine maker awaits regulatory approval from the WHO and others.
Novavax Stock Needs a Longer Pandemic as Investor Patience Wears Thin
Novavax has always been a volatile stock, as Covid-19 is its big chance for success. In the end, NVAX stock remains a speculation.
Novavax Is Looking More and More Like It Has Moderna-Type Potential
NVAX stock has languished as FDA approval seemed less likely. But that has all changed now. Novavax is almost certainly headed higher.
NVAX Stock: 2 Big Reasons Novavax Is Sliding Lower Today
Today, investors in Novavax are seeing a lot of red due to a key catalyst that's taking NVAX stock significantly lower.
Novavax: Big Market Potential, Meaningful Stock Upside
Even after a 5,690% gain, NVAX stock looks positioned for further upside with the firm's focus on bringing vaccines to low-income countries.
Novavax Has Growth Potential Both Now and After the Pandemic
Novavax has a Covid-19 vaccine already in production. With a world that still needs billions of doses, NVAX stock is positioned for growth.
Novavax and the Changing Covid-19 Vaccine Game
NVAX stock could still be a winner in the COVID-19 vaccine race, if Novavax can scale manufacturing and combine it with a flu shot.
Novavax Is a Short-Term Trade in a Long-Term Paradigm
Although NVAX stock has some near-term catalysts to rise on, the longer-term backdrop favors the vaccine competitors.
NVAX Stock: The Big Covid-19 News Sending Novavax Shooting Higher
NVAX stock is moving up today on plans to distribute its vaccine abroad. Even after failing to file with the FDA, investors are bullish.
Novavax Stock Will Reward the Very Patient in the Long Term
Are you familiar with the saying, “A watched pot never boils?” Owners of NVAX stock are likely very familiar and not happy about it.
Novavax Stock Has at Least Two Important Things Going for It
Novavax is a strong vaccine contender and the demand for vaccines is not going to slow down till next year. Buy NVAX stock in the dip.
Developed World Boosters Offer Big Market for Eventual Novavax Vaccine
Novavax’s combination vaccine and its Covid-19 vaccine sales for Q1/2022 in Japan are positive drivers for its revenue in the years ahead.
With the European Union Buying Doses, Novavax Has Plenty of Upside Left
Novavax secured a supply agreement with the European Union, which is a sign of confidence for its vaccine. NVAX stock could move higher from here.
Familiarity May Not Breed Contempt When It Comes to Novavax Stock
The Novavax vaccine might indeed reduce vaccine hesitancy in the United States. If that’s true than NVAX stock may have much more upside than I previously imagined.
Novavax Has More Room to Run as the Vaccination Push Carries On
With more overseas deals and its potential to still find success domestically in the booster-shot space, big upside remains for NVAX stock.
Novavax Stock Is Poised to Climb Further
NVAX stock seems positioned for further gains with the firm's vaccine deliveries set to begin in early 2022.
Novavax Will Enter the Covid-19 Vaccine Race With a Bang
NVAX stock trades at an attractive price compared with its peers as the market hasn't priced in its long-term growth potential.
